[Federal Register Volume 64, Number 205 (Monday, October 25, 1999)]
[Notices]
[Page 57472]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 99-27757]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
Opthalmic Drugs Subcommittee of the Dermatologic and Ophthalmic
Drugs Advisory Committee; Notice of Meeting
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
This notice announces a forthcoming meeting of a public advisory
committee of the Food and Drug Administration (FDA). The meeting will
be open to the public.
Name of Committee: Opthalmic Drugs Subcommittee of the Dermatologic
and Ophthalmic Drugs Advisory Committee.
General Function of the Committee: To provide advice and
recommendations to the agency on FDA's regulatory issues.
Date and Time: The meeting will be held on November 17, 1999, 8:30
a.m. to 5 p.m.
Location: Holiday Inn, Versailles Ballrooms I and II, 8120
Wisconsin Ave., Bethesda, MD.
Contact: Tracy Riley or Angie Whitacre, Center for Drug Evaluation
and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane,
Rockville, MD 20857, 301-827-7001, or FDA Advisory Committee
Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC
area), code 12534. Please call the Information Line for up-to-date
information on this meeting. Current information may also be accessed
on the Internet at FDA's website at www.fda.gov.
Agenda: The subcommittee will discuss new drug application 21-119
VisudyneTM (verteporfin for injection, QLT Therapeutics,
Inc.), for treatment of age-related macular degeneration in patients
with predominantly classic subfoveal choroidal neovascularization.
Procedure: Interested persons may present data, information, or
views, orally or in writing, on issues pending before the committee.
Written submissions may be made to the contact person by November 12,
1999. Oral presentations from the public will be scheduled between
approximately 8:30 a.m. and 9:30 a.m. Time allotted for each
presentation may be limited. Those desiring to make formal
presentations should notify the contact person before November 12,
1999, and submit a brief statement of the general nature of the
evidence or arguments they wish to present, the names and addresses of
proposed participants, and an indication of the approximate time
requested to make their presentation.
Notice of this meeting is given under the Federal Advisory
Committee Act (5 U.S.C. app. 2).
Dated: October 14, 1999.
Linda A. Suydam,
Senior Associate Commissioner.
[FR Doc. 99-27757 Filed 10-22-99; 8:45 am]
BILLING CODE 4160-01-F
